Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome

Medicine & Life Sciences

• Mifepristone 66%
• Cushing Syndrome 61%
• Glucocorticoid Receptors 57%
• Blood Pressure 32%
• Glucose 32%
• Area Under Curve 20%
• Glucose Intolerance 13%
• Arthralgia 13%
• Glycated Hemoglobin A 13%
• Waist Circumference 12%
• Potassium 11%
• Nausea 11%
• Hydrocortisone 11%
• Vomiting 11%
• Headache 11%
• Fatigue 10%
• Risk Assessment 10%
• Insulin Resistance 10%
• Edema 10%
• Fasting 10%
• Cognition 10%
• Type 2 Diabetes Mellitus 9%
• Depression 8%
• Health Care Outcome Assessment 8%
• Hypertension 8%
• Quality of Life 8%
• Weights and Measures 8%
• Morbidity 7%
• Safety 7%
• Mortality 6%
• Therapeutics 4%

Chemical Compounds

• Glucocorticoid Receptor Antagonist 100%
• Mifepristone 90%
• Metabolic 41%
• Glucose 37%
• Area Under the Curve 29%
• Blood Pressure 25%
• Cortisol 13%
• Thickening 12%
• Insulin Derivative 10%
• Hemoglobin 9%
• Disorder 8%
• Safety 8%
• Dose 7%
• Resistance 6%
• Plasma 6%
• Weight 5%